Alexion Pharmaceuticals (ALXN) Receives $163.44 Average PT from Analysts

Alexion Pharmaceuticals (NASDAQ:ALXN) has been assigned an average recommendation of “Buy” from the twenty-two brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $164.87.

ALXN has been the topic of several research analyst reports. Nomura upped their price objective on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a research note on Thursday, March 15th. Robert W. Baird set a $160.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. Cowen reissued a “buy” rating and set a $163.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, March 9th. Finally, Raymond James reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Monday, April 23rd.

In other Alexion Pharmaceuticals news, Director Christopher J. Coughlin acquired 10,000 shares of Alexion Pharmaceuticals stock in a transaction on Monday, April 30th. The shares were purchased at an average cost of $120.79 per share, with a total value of $1,207,900.00. Following the completion of the purchase, the director now owns 26,333 shares in the company, valued at $3,180,763.07. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John J. Orloff sold 2,115 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $118.53, for a total transaction of $250,690.95. Following the completion of the transaction, the executive vice president now directly owns 31,790 shares in the company, valued at $3,768,068.70. The disclosure for this sale can be found here. 4.35% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Delpha Capital Management LLC acquired a new stake in Alexion Pharmaceuticals in the fourth quarter worth $102,000. Point72 Asia Hong Kong Ltd raised its holdings in Alexion Pharmaceuticals by 3,156.7% in the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 947 shares during the period. CNB Bank acquired a new stake in Alexion Pharmaceuticals in the fourth quarter worth $150,000. Lucia Wealth Services LLC acquired a new stake in shares of Alexion Pharmaceuticals during the first quarter worth $191,000. Finally, Financial Gravity Wealth Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the first quarter worth $211,000. Institutional investors own 92.26% of the company’s stock.

Alexion Pharmaceuticals traded up $1.96, hitting $120.16, during trading hours on Friday, MarketBeat.com reports. 1,029,966 shares of the stock were exchanged, compared to its average volume of 1,987,761. The company has a current ratio of 3.35, a quick ratio of 2.86 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $25.97 billion, a price-to-earnings ratio of 23.29, a P/E/G ratio of 1.05 and a beta of 1.11. Alexion Pharmaceuticals has a 12 month low of $102.10 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.18. The firm had revenue of $930.90 million for the quarter, compared to analysts’ expectations of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 earnings per share. equities research analysts predict that Alexion Pharmaceuticals will post 6.28 EPS for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply